Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hetero
Hyderabad, Telangana, Indiahetero.com ↗
- Ownership
- Private
- Employees
- ~22000
- Development stage
- Other
01
Overview
Hetero supplies over 40% of global anti-retroviral APIs and finished dosage forms for HIV/AIDS, is a major supplier for influenza (oseltamivir), and rapidly launched generic COVID-19 antivirals (remdesivir, favipiravir), maintaining approvals for global commercial supply and partnerships with organizations like Gilead Sciences and RDIF. The company is active in multiple therapeutic areas including oncology, cardiology, anti-infectives, and APIs for global pharma partners.[1][2][3][7][9]
- Therapeutic areas
- OncologyInfectious DiseasesEndocrinologyCardiovascular
- Modalities
- Small moleculeBiologicBiosimilarVaccine
- Industry
- Pharma
02
Partnerships
Gilead Sciences (remdesivir license)Russian Direct Investment Fund (Sputnik V vaccine manufacturing)
Beyond the preview
Go deeper on Hetero.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hetero.